News|Videos|April 26, 2024
The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL
Author(s)Caron Jacobson, MD, Miguel-Angel Perales, MD
Thought leaders discuss patient scenarios and different factors to consider when deciding how to select and utilize bridging therapy in the management of patients with LBCL.
Advertisement
Episodes in this series
Advertisement
Related to this article
A single systemic dose of an immune-shielded lentiviral vector delivering the MMUT gene produced lasting metabolic correction in a mouse model of methylmalonic acidemia, according to newly published preclinical data.
The FDA approved Tregzi as the first allogeneic regulatory T cell-based immunotherapy based on Precision-T phase 3 data showing a significant 1-year cGVHD-free survival rate of 78% vs 38% with conventional alloHSC.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Advertisement
Advertisement